Author:
Pötzsch C.,Kurch Lars,Naumann S.,Georgi T. W.,Sabri O.,Stoevesandt D.,Cepelova M.,Körholz D.,Mauz-Körholz C.,Hasenclever D.,Kluge R.
Abstract
AbstractActivated brown fat (aBAT) is known to affect the evaluation of 18F-FDG PET scans, especially in young patients. The aim of this study was to determine factors influencing the occurrence of aBAT, and to investigate the effectiveness of the two preventive measures, warming and beta-blocker (propranolol) administration. Five-hundred-twenty-eight 18F-FDG-PET scans of 241 EuroNet-PHL-C2 trial patients from 41 nuclear medicine departments in Germany and Czech Republic were screened for aBAT. The occurrence of aBAT was analyzed with patient characteristics (age, sex, body mass index, predisposition to aBAT), weather data at the day of 18F-FDG PET scanning as well as the preventive measures taken. Potentially important factors from univariate analyses were included into a logistic regression model. Warming as a preventive measure was used in 243 18F-FDG-PET scans, propranolol was administered in 36, warming and propranolol were combined in 84, and no preventive measures were taken in 165 scans. Whereas age, sex and body mass index had no clear impact, there was an individual predisposition to aBAT. Logistic regression model revealed that the frequency of aBAT mainly depends on the outside temperature (p = 0.005) and can be effectively reduced by warming (p = 0.004), the administration of unselective beta-blocker or the combination of both. Warming is a simple, cheap and non-invasive method to reduce the frequency of aBAT. However, the effect of warming decreases with increasing outside temperatures. Administration of propranolol seems to be equally effective and provides advantages whenever the positive effect of warming is compromised. The combination of both preventive measures could have an additive effect.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Vali, R. et al. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0. JNM 62(1), 99–110. https://doi.org/10.2967/jnumed.120.254110 (2021).
2. Drubach, L.A., Palmer, E.L., Connolly, L.P., Baker, A., Zurakowski, D., Cypress, A.M. Pediatric brown adipose tissue: Detection, epidemiology, and differences from adults. J. Pediatr. 939–944 (2011).
3. Merkel, M., Schmid, S. M. & Iwen, K. A. Physiologie und klinische Bedeutung von weißem, beigem und braunem Fettgewebe. Der Internist 60, 115–121 (2019).
4. Sacks, H. & Symonds, M. E. Anatomical locations of human brown adipose tissue—Functional relevance and implications in obesity and type 2 diabetes. Diabetes 62, 1783–1790 (2013).
5. Hao, R., Yuan, L., Zhang, N., Li, C. & Yang, J. Brown adipose tissue: Distribution and influencing factors on FDG PET/CT scan. J. Pediatr. Endocr. Met. 25, 233–237 (2012).